<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-145-325</article-id>
<article-id pub-id-type="doi">10.26800/LV-145-9-10-7</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Health care</subject></subj-group>
</article-categories>
<title-group>
<article-title>Bjesno&#x0107;a i postekspozicijska antirabi&#x010D;na profilaksa u Primorsko-goranskoj &#x017E;upaniji od 1986. do 2021. godine</article-title>
<trans-title-group xml:lang="en">
<trans-title>Rabies and rabies postexposure prophylaxis in the Primorje-Gorski Kotar County from 1986 to 2021</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2472-6087</contrib-id><name><surname>Tomljenovi&#x0107;</surname><given-names>Morana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lako&#x0161;eljac</surname><given-names>Danijela</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dominik</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Rijeci</institution>, <addr-line>Rijeka</addr-line></aff>
<aff id="aff2"><label>2</label><institution>Nastavni zavod za javno zdravstvo Primorsko-goranske &#x017E;upanije</institution>, <addr-line>Rijeka</addr-line></aff>
<aff id="aff3"><label>3</label><institution>Fakultet zdravstvenih studija, Sveu&#x010D;ili&#x0161;te u Rijeci</institution>, <addr-line>Rijeka</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Doc. dr. sc. Morana Tomljenovi&#x0107;, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-2472-6087">https://orcid.org/0000-0003-2472-6087</ext-link>, Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Rijeci, Ul. Bra&#x0107;e Branchetta 20/1, 51000 Rijeka, e-po&#x0161;ta: <email xlink:href="tomljenovicmorana@gmail.com">tomljenovicmorana@gmail.com</email></corresp>
<fn fn-type="con">
<p content-type="fn-title">DOPRINOS AUTORA</p>
<p>K<sc>oncepcija</sc> <sc>ili</sc> <sc>nacrt</sc> <sc>rada</sc>: MT</p>
<p>P<sc>rikupljanje</sc>, <sc>analiza</sc> <sc>i</sc> <sc>interpretacija</sc> <sc>podataka</sc>: MZ, DL, SD</p>
<p>P<sc>isanje</sc> <sc>prve</sc> <sc>verzije</sc> <sc>rada</sc>: MT</p>
<p>K<sc>riti&#x010D;ka</sc> <sc>revizija</sc>: MT, DL, SD</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>11</month><year>2023</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>11</month><year>2023</year></pub-date>
<volume>145</volume>
<issue>9-10</issue>
<fpage>325</fpage>
<lpage>331</lpage>
<permissions>
<copyright-statement>Croatian Medical Association</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<sec><title>Cilj</title><p>Prikazati karakteristike antirabi&#x010D;ne za&#x0161;tite koja se provodi u antirabi&#x010D;noj ambulanti Epidemiolo&#x0161;kog odjela Rijeka Nastavnog zavoda za javno zdravstvo Primorsko-goranske &#x017E;upanije u razdoblju od 1986. do 2021. godine.</p></sec>
<sec><title>Ispitanici i metode</title><p>U istra&#x017E;ivanju su kori&#x0161;teni podatci antirabi&#x010D;nih anketa koje su dio godi&#x0161;njeg izvje&#x0161;&#x0107;a koje se dostavlja Referentnom centru Ministarstva zdravstva za bjesno&#x0107;u. Osobe koje su obra&#x0111;ivane i koje su primile antirabi&#x010D;nu za&#x0161;titu (imunoprofilaksu &#x2013; postekspozicijsko cijepljenje protiv bjesno&#x0107;e s humanim antirabi&#x010D;nim imunoglobulinom ili bez njega) najve&#x0107;im su udjelom stanovnici Primorsko-goranske &#x017E;upanije, odnosno grada Rijeke.</p></sec>
<sec><title>Rezultati</title><p>U antirabi&#x010D;noj ambulanti od 1986. do 2021. godine utvr&#x0111;en je trend smanjivanja broja pregledanih osoba (y= -6,9+304, R<sup>2</sup>=0,78; p&lt;0,05), s 263 na 50 osoba. Broj osoba koje su primile antirabi&#x010D;nu za&#x0161;titu u promatranome se periodu pove&#x0107;ao (y=0,95+19, R<sup>2</sup>=0,24; p&lt;0,05). U navedenome vremenskom razdoblju pregledano je 7.678 osoba, od kojih je 1.318 (17,2%) primilo imunoprofilaksu. Imunizirano je 42,3% (558/1.318) osoba &#x017E;enskoga spola i 57,7% osoba mu&#x0161;koga spola (760/1.318). Najve&#x0107;i broj osoba imuniziran je zbog ozljede, ogrebotine, kontakta od nepoznate, uginule, odlutale, ubijene ili divlje &#x017E;ivotinje (N=1005) (grupa C) te zbog ozljede, ogrebotine i kontakta sa &#x017E;ivotinjom pozitivnom na bjesno&#x0107;u (N=155) (grupa A). Osobe su naj&#x010D;e&#x0161;&#x0107;e imunizirane zbog ozljede, ogrebotine i kontakta sa psom (752/1318; 61,4%). Godine 2011. zabilje&#x017E;ena je posljednja osoba koja je imunizirana zbog kontakta s dokazano bijesnom &#x017E;ivotinjom.</p></sec>
<sec><title>Zaklju&#x010D;ak</title><p>U 35 godina rada antirabi&#x010D;ne ambulante na podru&#x010D;ju grada Rijeke nije zabilje&#x017E;ena bjesno&#x0107;a u ljudi, &#x0161;to se pripisuje u&#x010D;inkovitim mjerama antirabi&#x010D;ne za&#x0161;tite. Multidisciplinarni pristup pokazao se naju&#x010D;inkovitijim u smanjenju pobola od bjesno&#x0107;e u &#x017E;ivotinja te posljedi&#x010D;no sprje&#x010D;avanju pojave bjesno&#x0107;e u ljudi na podru&#x010D;ju Primorsko-goranske &#x017E;upanije i Republike Hrvatske. Me&#x0111;utim, neizostavno mjesto u prevenciji bjesno&#x0107;e u ljudi i dalje ima antirabi&#x010D;na imunoprofilaksa.</p></sec>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<sec><title>Aim</title><p>To present the characteristics of rabies preventive measures at the Antirabies Clinic at the Epidemiological Department of the Teaching Institute for Public Health Rijeka, Primorje-Gorski Kotar County, in the period from 1986 to 2021.</p></sec>
<sec><title>Respondents and methods</title><p>In this study, data from anti-rabies surveys included in the annual reports submitted to the Ministry of Health Rabies Reference Center were used. Persons who received antirabies protection (immunoprophylaxis &#x2013; vaccination against rabies with or without human rabies immunoglobulin) were mostly residents of the Primorje-Gorski Kotar County, dominantly from the city of Rijeka and its surroundings.</p></sec>
<sec><title>Results</title><p>In the period from 1986 to 2021, a decreasing trend in the number of examined persons at the Antirabies Clinic was determined (y=&#x2013;6.9+304, R<sup>2</sup>=0.78; p&lt;0.05), from 263 to 50 persons. During the study period the number of people who received protection against rabies increased (y=0.95+19, R<sup>2</sup>=0.24; p&lt;0.05).In this period 7678 persons were examined, out of which 1318 received immunoprophylaxis(17.2%). A total of 42.3% of females(558/1318) and 57.7% of males (760/1318) were immunized. Most people were vaccinated because of scratches, contacts from unknown, dead, stray, killed or wild animals (N=1005) (group C), or because of scratches and contacts with an animal tested positive for rabies (N=155) (group A). People were most often treated with antirabies treatment due to scratches or contact with a dog (752/1318; 57.1%). In 2011, the last person to receive antirabies treatment due to the contact with an animal tested positive for rabies was recorded.</p></sec>
<sec><title>Conclusion</title><p>In 35 years of operation of the Antirabies Clinic in Rijeka, no rabies cases have been recorded in humans, which can be attributed to effective antirabies protection measures. The multidisciplinary approach has proven to be the most effective in reducing the incidence of rabies in animals and consequently preventing the occurrence of rabies in humans from the Primorje-Gorski Kotar County and the Republic of Croatia. However, human anti-rabies immunoprophylaxis still plays an indispensable role in the prevention of rabies.</p></sec>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori BJESNO&#x0106;A &#x2013; epidemiologija, prevencija, veterinarstvo</kwd><kwd>CJEPIVO PROTIV BJESNO&#x0106;E</kwd><kwd>CIJEPLJENJE &#x2013; veterinarstvo</kwd><kwd>HRVATSKA &#x2013; epidemiologija</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>RABIES &#x2013; epidemiology, prevention and control, veterinary</kwd><kwd>RABIES VACCINES</kwd><kwd>VACCINATION &#x2013; veterinary</kwd><kwd>CROATIA &#x2013; epidemiology</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Bjesno&#x0107;a je akutna zarazna bolest sredi&#x0161;njega &#x017E;iv&#x010D;anog sustava uzrokovana virusom iz porodice <italic>Rabdoviridae</italic>, rod <italic>Lyssavirus</italic>. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) Rod <italic>Lyssavirus</italic> dijeli se na tri filogenetske grupe; prvoj filogenetskoj grupi pripadaju: <italic>Rabies lyssavirus</italic>, <italic>Duvenhage lyssavirus</italic>, <italic>European bat lyssaviruses</italic> tip 1 i 2, <italic>Bokeloh bat lyssavirus</italic>, <italic>Australian bat lyssavirus</italic>, <italic>Aravan lyssavirus</italic>, <italic>Khujand lyssavirus</italic> i <italic>Irkut lyssavirus</italic>, <italic>Taiwan bat lyssavirus</italic> i <italic>Gannoruwa bat lyssavirus</italic>; druga filogenetska grupa uklju&#x010D;uje <italic>Lagos bat lyssavirus</italic>, <italic>Mokola lyssavirus</italic> i <italic>Shimoni bat lyssavirus</italic>; u tre&#x0107;oj, neovisnoj filogenetskoj grupi nalaze se <italic>West Caucasian bat lyssavirus</italic>, <italic>Ikoma lyssavirus</italic> i <italic>Lleida bat lyssavirus</italic>. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) Najrasprostranjeniji i naj&#x010D;e&#x0161;&#x0107;i uzro&#x010D;nik bjesno&#x0107;e u ljudi jest <italic>Rabies lyssavirus</italic>. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)</p>
<p>Bjesno&#x0107;a spada u zoonoze. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Od bjesno&#x0107;e pobolijevaju sisavci, a glavni su rezervoar (izvor) virusa bjesno&#x0107;e &#x0161;i&#x0161;mi&#x0161;i. Mezokarnivori kao &#x0161;to su karnivori, rakuni, tvorovi, mungosi i jazavci naj&#x010D;e&#x0161;&#x0107;e imaju ulogu doma&#x0107;ina, dok kod <italic>Rabies lyssavirusa</italic> karnivori mogu biti i rezervoari. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) &#x010C;ovjek se naj&#x010D;e&#x0161;&#x0107;e inficira preko ugriza zara&#x017E;enoga psa. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Iako se smatra da je bjesno&#x0107;a gotovo uvijek smrtonosna, u ljudi je zabilje&#x017E;ena bjesno&#x0107;a bez smrtnog ishoda i bez prethodno primijenjene imunoprofilakse (primjena cjepiva protiv bjesno&#x0107;e i humanoga antirabi&#x010D;nog imunoglobulina). (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) U nekoliko istra&#x017E;ivanja utvr&#x0111;ena su i protutijela na bjesno&#x0107;u u ljudi koji nisu razvili simptome, &#x0161;to se interpretiralo kao mogu&#x0107;a izlo&#x017E;enost nepatogenom (za sada nepoznatom) virusu bjesno&#x0107;e, izlo&#x017E;enost virusu koji se ne mo&#x017E;e replicirati ili asimptomatska infekcija. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>)</p>
<p>Bjesno&#x0107;a u ljudi uzrokuje desetine tisu&#x0107;a smrti svake godine, uglavnom u Aziji i Africi. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) U Europi se godi&#x0161;nje naj&#x010D;e&#x0161;&#x0107;e prijavi nekoliko importiranih slu&#x010D;ajeva bjesno&#x0107;e; u ve&#x0107;ini zemalja autohtona bjesno&#x0107;a nije zabilje&#x017E;ena desetlje&#x0107;ima, (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) dok je broj oboljelih &#x017E;ivotinja zna&#x010D;ajno ve&#x0107;i. U 2021. godini potvr&#x0111;eno je 915 &#x017E;ivotinja pozitivnih na bjesno&#x0107;u: 467 (51%) slu&#x010D;ajeva u doma&#x0107;ih, 420 (46%) slu&#x010D;ajeva u divljih &#x017E;ivotinja te 28 (3%) slu&#x010D;ajeva u &#x0161;i&#x0161;mi&#x0161;a. Najve&#x0107;i je broj oboljelih &#x017E;ivotinja s podru&#x010D;ja Ukrajine (704; 77%) i Poljske (118; 13%). (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>)</p>
<p>U Hrvatskoj je posljednji autohtoni slu&#x010D;aj bjesno&#x0107;e u ljudi bio zabilje&#x017E;en 1964. godine, a nakon toga utvr&#x0111;ena su dva importirana oboljenja. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Od 1946. do 1964. godine na podru&#x010D;ju Republike Hrvatske zabilje&#x017E;ena su 44 slu&#x010D;aja bjesno&#x0107;e u ljudi. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) &#x0160;irenje bjesno&#x0107;e preko lisica iz Poljske i Rusije na teritorij Republike Hrvatske evidentirano je 1977. godine, nakon &#x0161;to deset godina nije zabilje&#x017E;ena zara&#x017E;ena &#x017E;ivotinja. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Na prostoru Republike Hrvatske prisutna je silvati&#x010D;na bjesno&#x0107;a koja se nije pro&#x0161;irila na otoke. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Rezervoar bjesno&#x0107;e u Republici Hrvatskoj i u Europi je crvena lisica. Bjesno&#x0107;a u &#x0161;i&#x0161;mi&#x0161;a u Republici Hrvatskoj nije utvr&#x0111;ena, ali su na nekoliko lokacija u &#x0161;i&#x0161;mi&#x0161;a dokazana protutijela na bjesno&#x0107;u (20/350; 5,7%). (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Posljednja bijesna &#x017E;ivotinja u Republici Hrvatskoj potvr&#x0111;ena je 2014. godine na podru&#x010D;ju Zagreba&#x010D;ke &#x017E;upanije, (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>, <xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) a na podru&#x010D;ju Primorsko-goranske &#x017E;upanije 2012. godine (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p>
<fig id="f1" position="float" fig-type="figure"><label>Figure 1</label><caption><p>R<sc>abies</sc> <sc>in</sc> <sc>animals</sc> <sc>in</sc> <sc>the</sc> P<sc>rimorje</sc>-G<sc>orski</sc> K<sc>otar</sc> C<sc>ounty</sc> <sc>from</sc> 1986 <sc>to</sc> 2021&#x2028;(Izvor podataka: Veterinarski zavod Rijeka / Data source: Veterinary Institute Rijeka)</p></caption><graphic xlink:href="LV-145-325-f1"></graphic></fig>
<p>Na podru&#x010D;ju Republike Hrvatske provodi se niz mjera za suzbijanje bjesno&#x0107;e u ljudi i &#x017E;ivotinja. U divljih &#x017E;ivotinja provodi se oralna imunizacija, u doma&#x0107;ih &#x017E;ivotinja zakonom je obavezna imunizacija pasa protiv bjesno&#x0107;e, dok je imunizacija ma&#x010D;aka i pitomih vretica preporu&#x010D;ena. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>, <xref ref-type="bibr" rid="r16"><italic>16</italic></xref>) Sojevi virusa koji se koriste u proizvodnji cjepiva za &#x017E;ivotinje (<italic>Challenge Virus Standard</italic> (CVS), <italic>Flury HEP</italic>, <italic>Kelev</italic>, <italic>Evelyn Rokitniki Abelseth</italic> (ERA), <italic>Vnukovo-32</italic>, <italic>Street Alabama Dufferin</italic> (SAD), <italic>Pasteur Virus</italic> (PV) i <italic>Pitmann Moore</italic> (PM), (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) uklju&#x010D;uju&#x0107;i i <italic>Flury LEP</italic>, koji se nalazi u cjepivu koje se primjenjuje u Republici Hrvatskoj u ljudi, (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) &#x0161;tite protiv <italic>Lyssavirusa</italic> filogrupe I za naju&#x010D;estalije viruse, a za&#x0161;tita koja se posti&#x017E;e tim cjepivima za viruse iz filogrupe II i III smatra se nedovoljnom. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>, <xref ref-type="bibr" rid="r19"><italic>19</italic></xref>) U Republici Hrvatskoj izolirani sojevi virusa iz &#x017E;ivotinja pripadaju virusu <italic>Rabies</italic> iz filogrupe I. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>)</p>
<p>U ljudi se antirabi&#x010D;na za&#x0161;tita pru&#x017E;a u antirabi&#x010D;nim ambulantama Zavoda za javno zdravstvo, a na podru&#x010D;ju Primorsko-goranske &#x017E;upanije gotovo kontinuirano od 1932. godine, kada je s radom zapo&#x010D;ela antirabi&#x010D;na ambulanta u Domu narodnog zdravlja Su&#x0161;ak. Antirabi&#x010D;na obrada podrazumijeva uzimanje anamneze, pregled rane i, prema procjeni, primjenu antirabi&#x010D;ne za&#x0161;tite, tj. postekspozicijske imunoprofilakse (imunizacije &#x2013; cijepljenja). Imunizacija se provodi prema Essenskoj shemi (5 doza; 0-3-7-4-28 dan) koja se kod nas primjenjivala do 90-ih godina ili Zagreba&#x010D;koj shemi (4 doze; 0-0-7-21 dan), koja se primjenjuje do danas primjenom humanoga antirabi&#x010D;nog imunoglobulina ili bez njega. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>, <xref ref-type="bibr" rid="r20"><italic>20</italic></xref>) Zagreba&#x010D;ku shemu imunizacije, nakon &#x0161;to ju je 1986. godine odobrio Pasteurov institut u Francuskoj, (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>) preporu&#x010D;ila je i Svjetska zdravstvena organizacija.</p>
<p>Cilj ovog rada jest prikazati karakteristike antirabi&#x010D;ne za&#x0161;tite koja se provodi u antirabi&#x010D;noj ambulanti Epidemiolo&#x0161;kog odjela Rijeka Nastavnog zavoda za javno zdravstvo Primorsko-goranske &#x017E;upanije od 1986. do 2021. godine.</p>
<sec sec-type="other1">
<title>Ispitanici i metode</title>
<p>Antirabi&#x010D;na ambulanta Epidemiolo&#x0161;kog odjela Rijeka Nastavnoga zavoda za javno zdravstvo jedna je od osam antirabi&#x010D;nih ambulanti na podru&#x010D;ju Primorsko-goranske &#x017E;upanije u kojoj se odra&#x0111;uje najve&#x0107;i dio pregleda zbog ugriza/kontakta sa &#x017E;ivotinjom sumnjivom na bjesno&#x0107;u. Najve&#x0107;i broj osoba koje su pregledane i koje su primile antirabi&#x010D;nu za&#x0161;titu stanovnici su Primorsko-goranske &#x017E;upanije, odnosno grada Rijeke.</p>
<p>U istra&#x017E;ivanju su kori&#x0161;teni podatci antirabi&#x010D;nih anketa provedenih od 1986. do 2021. godine. Osobe koje su primile antirabi&#x010D;nu za&#x0161;titu (imunoprofilaksu) u anketama se evidentiraju kao tretirane. Podatci iz anketa obra&#x0111;eni su prema spolu, dobi, mjestu ozljede, vrsti &#x017E;ivotinje koja je nanijela ozljedu te prema na&#x010D;inu postekspozicije. Podatci iz ankete dio su godi&#x0161;njeg izvje&#x0161;&#x0107;a koji se dostavlja Referentnom centru Ministarstva zdravstva za bjesno&#x0107;u. Podatci za postekspozicijsku profilaksu prezentirani u ovome radu raspodijeljeni su u &#x010D;etiri razdoblja: 1986. &#x2013; 1993., 1994. &#x2013; 2002., 2003. &#x2013; 2009. i 2010. &#x2013; 2021. Kori&#x0161;teni su prethodno agregirani podatci jer ne postoji mogu&#x0107;nost pristupa pojedinoj godini starijega datuma.</p>
<p>Podatci su prikazani u apsolutnim i relativnim brojevima. Za obradu analize trenda antirabi&#x010D;no tretiranih pacijenata kori&#x0161;tena je linearna regresija. Razina statisti&#x010D;ke zna&#x010D;ajnosti odre&#x0111;ena je s P&lt;0,05. Podatci su obra&#x0111;eni u programima <italic>Microsoft Excel 2016</italic> i <italic>StatCorp LP Stata 13</italic>.</p>
</sec>
<sec sec-type="other2">
<title>Rezultati</title>
<p>U antirabi&#x010D;noj ambulanti Epidemiolo&#x0161;koga odjela Rijeka od 1986. do 2021. godine pregledano je 7.678 osoba zbog sumnje na zarazu bjesno&#x0107;om, zbog koje je 1.318 (17,2%) osoba primilo imunoprofilaksu (postekspozicijska antirabi&#x010D;na profilaksa), a 6.360 (82,8%) osoba nije primilo. U navedenome razdoblju utvr&#x0111;en je trend smanjivanja broja pregledanih osoba, broj imuniziranih smanjio se od 263 na po&#x010D;etku promatranoga razdoblja do 50 osoba na kraju promatranoga razdoblja (y=-6,9+304, R<sup>2</sup>=0,78; p&lt;0,05). Broj imuniziranih osoba pove&#x0107;ao se u promatranome periodu (y=0,95+19, R<sup>2</sup>=0,24; p&lt;0,05) (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p>
<fig id="f2" position="float" fig-type="figure"><label>Figure 2</label><caption><p>Post-exposure rabies prophylaxis of the Antirabies Clinic in Rijeka from 1986 to 2021</p></caption><graphic xlink:href="LV-145-325-f2"></graphic></fig>
<p>Najve&#x0107;i broj osoba cijepljen je zbog ozljede, ogrebotine, kontakta od nepoznate, uginule, odlutale, ubijene ili divlje &#x017E;ivotinje (N=1005) (grupa C) te zbog ozljede, ogrebotine, kontakta sa &#x017E;ivotinjom pozitivnom na bjesno&#x0107;u (N=155) (grupa A). Ukupno su 62 osobe (4,7%) primile kompletnu antirabi&#x010D;nu za&#x0161;titu: cjepivo i humani antirabi&#x010D;ni imunoglobulin (<xref ref-type="table" rid="t1">Table 1</xref>).</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Rabies post-exposure prophylaxis in humans at the Rijeka Antirabies Clinic from 1986 to 2021</title>
</caption>
<table frame="hsides" rules="groups">
<col width="25.46%"/>
<col width="17.75%"/>
<col width="11.24%"/>
<col width="11.24%"/>
<col width="11.83%"/>
<col width="12.42%"/>
<col width="10.06%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Grupa / Group</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Podjela prema na&#x010D;inu postekspozicije<break/>/ postexposure prophylaxis</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1986. &#x2013;1993.<break/>N (%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1994. &#x2013;2002.<break/>N (%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2003. &#x2013; 2009.<break/>N (%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2010. &#x2013; 2021.*<break/>N (%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Ukupno / Total<break/>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">A: ozljeda (ugriz, ogrebotina, kontakt) od utvr&#x0111;eno bijesne &#x017E;ivotinje / Injury (bite, scratch, contact with saliva) inflicted by proven rabid animal</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">imunizacija<break/>/ vaccination</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">51 (32,9)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7 (4,5)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">72 (46,5)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">8 (5,2)</td>
<td rowspan="2" valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt; background-color:rgb(198,217,241)">155 (100)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">imunizacija+ imunoglobulin<break/>/ vaccination+<break/>immunoglobulin</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7 (4,5)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">5 (3,2)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3 (1,9)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2 (1,3)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">B: ozljeda (ugriz, ogrebotina, kontakt) od &#x017E;ivotinje sumnjive na bjesno&#x0107;u / Injury inflicted by an animal suspected of rabies</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">imunizacija<break/>/ vaccination</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7 (7,4)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">12 (12,6)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">13 (13,7)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">50 (52,6)</td>
<td rowspan="2" valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt; background-color:rgb(198,217,241)">95 (100)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">imunizacija+ imunoglobulin<break/>/ vaccination+<break/>immunoglobulin</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0 (0)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2 (2,1)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2 (2,1)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">9 (9,5)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">C: ozljeda (ugriz, ogrebotina, kontakt) od nepoznate, uginule, odlutale, ubijene ili divlje &#x017E;ivotinje / Injury inflicted by an unknown, dead, stray, killed or wild animal</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">imunizacija<break/>/ vaccination</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">109 (10,8)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">116 (11,5)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">308 (30,6)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">440 (43,8)</td>
<td rowspan="2" valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt; background-color:rgb(198,217,241)">1.005 (100)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">imunizacija+ imunoglobulin<break/>/ vaccination+<break/>immunoglobulin</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0 (0)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0 (0)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">16 (1,6)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">16 (1,6)</td>
</tr>
<tr>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">D: ozljeda (ugriz, ogrebotina, kontakt) od &#x017E;ivotinje koja je nakon 10 dana nadzora ostala zdrava / Injury inflicted by an animal that remained healthy after 10 days of veterinarian surveillance</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">imunizacija<break/>/ vaccination</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">36 (57,1)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4 (6,4)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7 (11,1)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">16 (25,4)</td>
<td rowspan="2" valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt; background-color:rgb(198,217,241)">63 (100)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">imunizacija+ imunoglobulin<break/>/ vaccination+<break/>immunoglobulin</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0 (0)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0 (0)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0 (0)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0 (0)</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>* Godine 2011. zabilje&#x017E;ena je posljednja osoba tretirana zbog kontakta s dokazano bijesnom &#x017E;ivotinjom. / The last person immunized for contact with a proven rabid animal was recorded in 2011.</p>
</table-wrap-foot></table-wrap>
<p>U antirabi&#x010D;noj ambulanti cijepljeno je 42,3% (558/1.318) osoba &#x017E;enskoga spola i 57,7% osoba mu&#x0161;koga spola (760/1.318).</p>
<p>Najve&#x0107;i udio cijepljenih osoba nalazi se u dobnoj skupini od 21 do 40 godina (405/1318; 30,7%) (<xref ref-type="table" rid="t2">Table 2</xref>).</p>
<table-wrap id="t2" position="float">
<label>Table 2</label><caption><title>Distribution of vaccinated people according to age groups at the Rijeka Antirabies Clinic from 1986 to 2021</title>
</caption>
<table frame="hsides" rules="groups">
<col width="36.59%"/>
<col width="63.41%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Dobne skupine<break/>/Age groups</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Cijepljene osobe / Vaccinated persons<break/>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">0 &#x2013; 20</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt; background-color:rgb(198,217,241)">299 (22,7)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">21 &#x2013; 40</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt; background-color:rgb(198,217,241)">405 (30,7)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">41 &#x2013; 60</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt; background-color:rgb(198,217,241)">389 (29,5)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">61 i vi&#x0161;e /and over</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt; background-color:rgb(198,217,241)">225 (17,1)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Ukupno /Total</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt; background-color:rgb(198,217,241)">1.318 (100)</td>
</tr>
</tbody></table></table-wrap>
<p>Osobe su naj&#x010D;e&#x0161;&#x0107;e antirabi&#x010D;no cijepljene zbog ozljede gornjega ekstremiteta (708/1.318; 53,7%) (<xref ref-type="table" rid="t3">Table 3</xref>).</p>
<table-wrap id="t3" position="float">
<label>Table 3</label><caption><title>Type and place of injury of vaccinated persons at the Rijeka Antirabies Clinic from 1986 to 2021</title>
</caption>
<table frame="hsides" rules="groups">
<col width="14.64%"/>
<col width="48.78%"/>
<col width="36.58%"/>
<thead>
<tr>
<th valign="middle" colspan="2" align="left" scope="colgroup" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Vrsta i mjesto ozljede<break/>/ Type and place of injury</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Cijepljene osobe<break/>/ Vaccinated persons<break/>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="5" valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Ugriz<break/>/ Bite</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">donji ekstremiteti<break/>/ lower limbs</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">397 (30,1)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">gornji ekstremiteti<break/>/ upper limbs</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">708 (53,7)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">trup / trunk</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">36 (2,7)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">glava,vrat / head, neck</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">52 (3,9)</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">vi&#x0161;e mjesta / multiple injuries</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">34 (2,7)</td>
</tr>
<tr>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Kontakt / Contact</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">91 (6,9)</td>
</tr>
<tr>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Ukupno / Total</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">1.318 (100)</td>
</tr>
</tbody></table></table-wrap>
<p>Osobe su naj&#x010D;e&#x0161;&#x0107;e antirabi&#x010D;no cijepljene zbog ozljede, ogrebotine, kontakta sa psom (752/1.318; 57,1%) i ma&#x010D;kom (290/1.318; 22%) (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p>
<fig id="f3" position="float" fig-type="figure"><label>Figure 3</label><caption><p>Animal species for which rabies protection was used in humans</p></caption><graphic xlink:href="LV-145-325-f3"></graphic></fig>
</sec>
<sec sec-type="other3">
<title>Rasprava</title>
<p>Antirabi&#x010D;na za&#x0161;tita u Republici Hrvatskoj provodi se dugi niz godina i pru&#x017E;a se jedino u antirabi&#x010D;nim ambulantama epidemiolo&#x0161;kih odjela Zavoda za javno zdravstvo &#x010D;ije aktivnosti nadzire Referentni centar Ministarstva zdravstva za bjesno&#x0107;u pri Nastavnome zavodu za javno zdravstvo &#x201E;Dr. Andrija &#x0160;tampar&#x201C; u Zagrebu. Osim primjene postekspozicijske imunoprofilakse, u prevenciji bjesno&#x0107;e koristi se i preeskspozicijska imunoprofilaksa prema shemi 0-7-21(28) dan koja se preporu&#x010D;uje kod osoba/zanimanja kod kojih postoji pove&#x0107;ani rizik od zaraze bjesno&#x0107;om. (<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>) U Nastavnom zavodu za javno zdravstvo Primorsko-goranske &#x017E;upanije manje od deset osoba godi&#x0161;nje primi preeskpozicijsku imunoprofilaksu (<italic>internal data</italic>). Broj osoba koje su pregledane zbog antirabi&#x010D;ne za&#x0161;tite u Primorsko-goranskoj &#x017E;upaniji tijekom godina se postupno smanjivao. Pad broja pregledanih osoba uslijedio je nakon Domovinskog rata. U sljede&#x0107;im godinama pobolj&#x0161;ala se skrb za napu&#x0161;tene &#x017E;ivotinje, incidencija bjesno&#x0107;e u &#x017E;ivotinja je bila sve manja, pa se mo&#x017E;e pretpostaviti da je to utjecalo na percepcija rizika i na manji broj posjeta pacijenata Antirabi&#x010D;noj ambulanti. U promatranom vremenskom periodu broj tretiranih osoba se pove&#x0107;ao, povremeni ve&#x0107;i broj pregleda pojedinih godina prati godine u kojima je zabilje&#x017E;en pove&#x0107;an broj pozitivnih &#x017E;ivotinja na bjesno&#x0107;u (1989. &#x2013; 1993., 2007. &#x2013; 2008.) (<xref ref-type="fig" rid="f1">Figure 1</xref>, <xref ref-type="fig" rid="f2">Figure 2</xref>). Od 2003. do 2021. raste udio tretiranih zbog ugriza/kontakta od nepoznate &#x017E;ivotinje (kategorija C). Prema podatcima Referentnog centara Ministarstva zdravstva za bjesno&#x0107;u u periodu od 2008. do 2013. godine, Primorsko-goranska &#x017E;upanija zauzima s 26,1% tretiranih osoba sredi&#x0161;nje mjesto u odnosu na udio tretiranih u drugim &#x017E;upanijama (14,2% Istarska &#x017E;upanija &#x2013; 59,1% Dubrova&#x010D;ko-<strike>n</strike>eretvanska &#x017E;upanija). (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) U drugom istra&#x017E;ivanju, prema izvje&#x0161;taju Antirabi&#x010D;ne ambulante Grada Zagreba, zabilje&#x017E;en je porast broja tretiranih osoba, od 1995. do 2014. godine, na 24%. (<xref ref-type="bibr" rid="r22"><italic>22</italic></xref>) Kako nije evidentirano znatnije odstupanje u broju tretiranih u odnosu na druge &#x017E;upanije, mo&#x017E;e se zaklju&#x010D;iti da su na&#x0161;i rezultati posljedica epidemiolo&#x0161;kih indikacija i trenuta&#x010D;ne stru&#x010D;ne prakse. Broj pregledanih osoba 2020. i 2021. bio je najmanji u promatranome vremenskom periodu, kao posljedica mjera i ograni&#x010D;avanja kretanja uzrokovanih pandemijom koronavirusa.</p>
<p>U Republici Hrvatskoj od 1977. do 2017. godine najve&#x0107;i udio &#x017E;ivotinja pozitivnih na bjesno&#x0107;u zabilje&#x017E;en je 1994. godine (540/2.239; 31,8%), a najve&#x0107;i broj pozitivnih &#x017E;ivotinja zabilje&#x017E;en je 2000. godine (1042/7.909; 13,2%). Iako se godi&#x0161;nje uzorkovao razli&#x010D;it broj &#x017E;ivotinja, 2016. i 2017. godine zabilje&#x017E;en je broj manji od 1.000, dok je npr. 2000. godine broj uzorkovanih &#x017E;ivotinja iznosio osam puta vi&#x0161;e. U tome razdoblju naj&#x010D;e&#x0161;&#x0107;e testirane &#x017E;ivotinje (N=108, 190) na bjesno&#x0107;u bile su lisice (61%), a petina je bila pozitivna na bjesno&#x0107;u. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Broj pregledanih &#x017E;ivotinja zbog sumnje na bjesno&#x0107;u tako&#x0111;er se tijekom godina smanjio i u Primorsko-goranskoj &#x017E;upaniji. Godine 2008. zabilje&#x017E;en je najve&#x0107;i broj pregledanih &#x017E;ivotinja (1.366 &#x017E;ivotinja), a 2021. godine najmanji broj (19 &#x017E;ivotinja) (<xref ref-type="fig" rid="f1">Figure 1</xref>). Svake godine Uprava za veterinarstvo i sigurnost hrane odre&#x0111;uje broj &#x017E;ivotinja (lisica i &#x010D;agljeva) koje je potrebno testirati na bjesno&#x0107;u. Broj preporu&#x010D;enih uzoraka odre&#x0111;uje se ovisno o epizoolo&#x0161;koj i epidemiolo&#x0161;koj situaciji te prema podru&#x010D;ju lovi&#x0161;ta i kvadratnom kilometru. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) Iako postoje stimulacije da se osigura broj preporu&#x010D;enih uzoraka, pojedinih godina bilo je odstupanja od predvi&#x0111;enog broja s najve&#x0107;im razlikama u vrijeme pandemije COVID-19.</p>
<p>Godine 2011. po&#x010D;ela se provoditi sustavna i organizirana oralna imunizacija divljih &#x017E;ivotinja na podru&#x010D;ju Republike Hrvatske te se dvaput godi&#x0161;nje putem zrakoplova pola&#x017E;u mamci koji sadr&#x017E;e cjepivo. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Oralna imunizacija provodila se i prije 2011. godine, ali sporadi&#x010D;no i na podru&#x010D;ju pojedinih &#x017E;upanija Republike Hrvatske. Porast i pad broja potvr&#x0111;eno bijesnih &#x017E;ivotinja u Primorsko-goranskoj &#x017E;upaniji u periodu do 2011. godine mo&#x017E;e se obrazlo&#x017E;iti upravo tim povremenim oralnim imunizacijama divljih &#x017E;ivotinja (<xref ref-type="fig" rid="f1">Figure 1</xref>). Nedugo nakon sustavnoga provo&#x0111;enja oralne imunizacije divljih &#x017E;ivotinja, 2011. godine cijepila se zadnja osoba protiv bjesno&#x0107;e zbog kontakta s utvr&#x0111;eno bijesnom &#x017E;ivotinjom, a 2012. godine potvr&#x0111;en je posljednji slu&#x010D;aj bjesno&#x0107;e u &#x017E;ivotinja na podru&#x010D;ju Primorsko-goranske &#x017E;upanije.</p>
<p>Isto&#x010D;na Europa redovito bilje&#x017E;i ve&#x0107;i broj slu&#x010D;ajeva bjesno&#x0107;e u &#x017E;ivotinja i predstavlja opasnost za dr&#x017E;ave Zapadne Europe koje su eliminirale bjesno&#x0107;u. (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) S obzirom na to da Ukrajina godinama ima najve&#x0107;i broj bijesnih &#x017E;ivotinja, (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) rat koji je zapo&#x010D;eo 2022. godine sigurno &#x0107;e imati negativan utjecaj na suzbijanje bjesno&#x0107;e u Europi. Susjedne zemlje Slovenija, Ma&#x0111;arska, Srbija te Bosna i Hercegovina (BiH) uklju&#x010D;ene su u isti projekt suzbijanja bjesno&#x0107;e kao i Republika Hrvatska. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>)</p>
<p>Godine 2020. utvr&#x0111;ena je bjesno&#x0107;a u psa u BiH (Srebrenica), &#x0161;est godina od posljednje pozitivne &#x017E;ivotinje. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) Srbija je 2018. godine imala posljednju pozitivnu &#x017E;ivotinju (lisica), blizu granice s BiH, a u Ma&#x0111;arskoj su 2017. godine utvr&#x0111;ene posljednje tri bijesne &#x017E;ivotinje (dvije doma&#x0107;e &#x017E;ivotinje, jedna divlja &#x017E;ivotinja). Slovenija ima status zemlje slobodne od bjesno&#x0107;e sa zabilje&#x017E;enom zadnjom bjesno&#x0107;om 2013. godine. Crna Gora je ve&#x0107; 2012. godine imala posljednju potvr&#x0111;enu bjesno&#x0107;u, ali nije ostvarila uvjete za status zemlje slobodne od bjesno&#x0107;e. (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>, <xref ref-type="bibr" rid="r26"><italic>26</italic></xref>) U zemljama isto&#x010D;ne Europe &#x010D;esto izostaje kontinuirani nadzor nad mjerama za eliminaciju bjesno&#x0107;e, gdje se uzorkovanje i oralna imunizacija ne provode sustavno. Oralna imunizacija divljih &#x017E;ivotinja planira se, na cjelokupnome teritoriju Republike Hrvatske, provoditi sve do 2022. godine zbog pojave bjesno&#x0107;e u BiH, a zatim prema epidemiolo&#x0161;koj indikaciji. Podru&#x010D;ja s pove&#x0107;anim rizikom za pojavu bjesno&#x0107;e bit &#x0107;e i dalje tretirana. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>)</p>
<p>U Republici Hrvatskoj provodi se niz mjera protiv bjesno&#x0107;e kao &#x0161;to su: imunizacija pasa, oralna imunizacija divljih &#x017E;ivotinja, preekspozicijska za&#x0161;tita u rizi&#x010D;ne populacije i postekspozicijska za&#x0161;tita u izlo&#x017E;enih, edukacija op&#x0107;e populacije i struke, nadzor nad mjerama protiv bjesno&#x0107;e itd. Mjere imunizacije u ljudi pokazale su se u&#x010D;inkovitima te u ljudi nije zabilje&#x017E;ena bjesno&#x0107;a dugi niz godina. Unato&#x010D; tomu &#x0161;to posljednjih godina nemamo potvr&#x0111;enu bjesno&#x0107;u u Republici Hrvatskoj, smjernice za primjenu postekspozicijske antirabi&#x010D;ne imunoprofilakse u ljudi za sada se nisu mijenjale. Zahvaljuju&#x0107;i povoljnoj epidemiolo&#x0161;koj situaciji mo&#x017E;e se o&#x010D;ekivati da &#x0107;e se broj pregleda i tretiranih u budu&#x0107;nosti smanjiti. Djelomi&#x010D;na imunizacija pasa, unato&#x010D; zakonskoj obavezi, polu&#x010D;ila je i djelomi&#x010D;ne rezultate te je eliminirana urbana bjesno&#x0107;a. Tek je sustavno i sistematizirano primijenjena mjera, kao &#x0161;to je oralna imunizacija divljih &#x017E;ivotinja (lisica), napravila zna&#x010D;ajan pomak u eliminaciji bjesno&#x0107;e. Intenzivne preventivne mjere koje su primjenjivane protiv &#x0161;irenja bjesno&#x0107;e omogu&#x0107;ile su Hrvatskoj da 2021. godine dobije status zemlje slobodne od bjesno&#x0107;e. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>) Odr&#x017E;avanje statusa zemlje slobodne od bjesno&#x0107;e svakako ovisi i o incidenciji bjesno&#x0107;e u susjednim zemljama jer pojedine &#x017E;ivotinje, posebno lisice, imaju radijus kretanja od oko deset kilometara na dan, (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>) stoga je od velike va&#x017E;nosti suzbiti bjesno&#x0107;u i u susjednim dr&#x017E;avama.</p>
<p>Iako je Hrvatska, kao i neke druge dr&#x017E;ave u Europi, slobodna od &#x201E;zemaljske&#x201C; (klasi&#x010D;ne) bjesno&#x0107;e, uvijek postoji rizik od &#x201E;prelijevanja&#x201C; bjesno&#x0107;e sa &#x0161;i&#x0161;mi&#x0161;a na druge vrste &#x017E;ivotinja. Pojedina istra&#x017E;ivanja pokazala su djelotvornost cjepiva protiv bjesno&#x0107;e i u &#x0161;i&#x0161;mi&#x0161;a, (<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) ali je malo vjerojatno da &#x0107;e se pristupiti njihovom cijepljenju. Nadalje, postoji mogu&#x0107;nost ponovnog unosa bjesno&#x0107;e trgovinom i prometom &#x017E;ivotinja i ljudi. Da bi se odr&#x017E;ao status zemlje slobodne od bjesno&#x0107;e potrebno je nastaviti sa svim navedenim mjerama uz multidisciplinarnu suradnju razli&#x010D;itih profila stru&#x010D;njaka i populacije kako bismo u kona&#x010D;nici imali Europu slobodnu od bjesno&#x0107;e.</p>
<p>Kao najzna&#x010D;ajnija ograni&#x010D;enja u ovom istra&#x017E;ivanju istaknuli bismo sljede&#x0107;e. Prikazani su podatci o antirabi&#x010D;noj za&#x0161;titi Antirabi&#x010D;ne ambulatne u Rijeci koja je jedna od osam ambulanti na podru&#x010D;ju Primorsko-goranske &#x017E;upanije koje pru&#x017E;aju uslugu cijepljenja protiv bjesno&#x0107;e. Iako se u antirabi&#x010D;noj ambulanti u Rijeci pregleda najve&#x0107;i broj pacijenata u odnosu na druge ambulante, rezultati dobiveni u ovom istra&#x017E;ivanju nisu nu&#x017E;no reprezentativni za cijelu &#x017E;upaniju. Neki podatci su prikazani u prethodno agregiranom obliku jer pojedina&#x010D;ni podatci nisu bili sa&#x010D;uvani. Interpretacija i kvaliteta podataka vjerojatno bi bila bolja s pojedina&#x010D;nim podatcima.</p>
</sec>
<sec sec-type="other4">
<title>Zaklju&#x010D;ak</title>
<p>U 35 godina rada antirabi&#x010D;ne ambulante na podru&#x010D;ju grada Rijeke nije zabilje&#x017E;ena nijedna osoba s humanom bjesno&#x0107;om, &#x0161;to se mo&#x017E;e pripisati u&#x010D;inkovitim mjerama antirabi&#x010D;ne za&#x0161;tite u ljudi. Me&#x0111;utim, tek se multidisciplinarni pristup pokazao djelotvornim u smanjenju pobola od bjesno&#x0107;e u &#x017E;ivotinja, a time i sprje&#x010D;avanju pojave bjesno&#x0107;e u ljudi na podru&#x010D;ju grada Rijeke, Primorsko-goranske &#x017E;upanije, odnosno Republike Hrvatske. Iako se naju&#x010D;inkovitijom mjerom za eliminaciju bjesno&#x0107;e pokazala oralna imunizacija divljih &#x017E;ivotinja, neizostavno mjesto u prevenciji bjesno&#x0107;e u ljudi i dalje &#x010D;ini antirabi&#x010D;na imunoprofilaksa.</p>
</sec>
</body>
<back>
<ack>
<title>Zahvala</title>
<p>Zahvaljujemo Veterinarskom zavodu Rijeka na dostavljenim podatcima o bjesno&#x0107;i u &#x017E;ivotinja na podru&#x010D;ju Primorsko-goranske &#x017E;upanije.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<p content-type="fn-title">INFORMACIJE O SUKOBU INTERESA</p>
<p>Autori nisu deklarirali sukob interesa relevantan za ovaj rad.</p>
</fn>
<fn fn-type="financial-disclosure">
<p content-type="fn-title">INFORMACIJA O FINANCIRANJU</p>
<p>Za ovaj &#x010D;lanak nisu primljena financijska sredstva.</p>
</fn>
</fn-group>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>PJ</given-names></name><name><surname>Freitas-Ast&#x00FA;a</surname><given-names>J</given-names></name><name><surname>Bejerman</surname><given-names>N</given-names></name><name><surname>Blasdell</surname><given-names>KR</given-names></name><name><surname>Breyta</surname><given-names>R</given-names></name><name><surname>Dietzgen</surname><given-names>RG</given-names></name><etal/></person-group> <article-title>ICTV Virus Taxonomy Profile: Rhabdoviridae.</article-title> <source>J Gen Virol</source>. <year>2022</year>;<volume>103</volume>: <pub-id pub-id-type="doi">10.1099/jgv.0.001020</pub-id><pub-id pub-id-type="pmid">35723908</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="web">World Health Organization. Rabies Bulletin &#x2013; Europe, classification [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who-rabies-bulletin.org/node/54">https://www.who-rabies-bulletin.org/node/54</ext-link>. [Pristupljeno 21. 10. 2022.]</mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="web">World Health Organization. Rabies, key facts [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/rabies">https://www.who.int/news-room/fact-sheets/detail/rabies</ext-link>. [Pristupljeno 21. 10. 2022.]</mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupprecht</surname><given-names>C</given-names></name><name><surname>Kuzmin</surname><given-names>I</given-names></name><name><surname>Meslin</surname><given-names>F</given-names></name></person-group>. <article-title>Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies.</article-title> <source>F1000Res</source>. <year>2017</year>;<volume>6</volume>:<fpage>184</fpage>. <pub-id pub-id-type="doi">10.12688/f1000research.10416.1</pub-id><pub-id pub-id-type="pmid">28299201</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willoughby</surname><given-names>RE</given-names><suffix>Jr</suffix></name><name><surname>Tieves</surname><given-names>KS</given-names></name><name><surname>Hoffman</surname><given-names>GM</given-names></name><name><surname>Ghanayem</surname><given-names>NS</given-names></name><name><surname>Amlie-Lefond</surname><given-names>CM</given-names></name><name><surname>Schwabe</surname><given-names>MJ</given-names></name><etal/></person-group> <article-title>Survival after treatment of rabies with induction of coma.</article-title> <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>24</issue>):<fpage>2508</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa050382</pub-id><pub-id pub-id-type="pmid">15958806</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group>. <article-title>Recovery of a patient from clinical rabies &#x2013; California, 2011.</article-title> <source>MMWR Morb Mortal Wkly Rep</source>. <year>2012</year>;<volume>3</volume>(<issue>61</issue>):<fpage>61</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducrocq</surname><given-names>J</given-names></name><name><surname>Proulx</surname><given-names>JF</given-names></name><name><surname>L&#x00E9;vesque</surname><given-names>B</given-names></name><name><surname>De Serres</surname><given-names>G</given-names></name><name><surname>Wood</surname><given-names>H</given-names></name><name><surname>Lemire</surname><given-names>M</given-names></name></person-group>. <article-title>Assessment of naturally acquired neutralizing antibodies against rabies Lyssavirus in a subset of Nunavik&#x2019;s Inuit population considered most at risk of being exposed to rabid animals.</article-title> <source>Zoonoses Public Health</source>. <year>2019</year>;<volume>66</volume>:<fpage>533</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/zph.12561</pub-id><pub-id pub-id-type="pmid">30688040</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>AT</given-names></name><name><surname>Petersen</surname><given-names>BW</given-names></name><name><surname>Recuenco</surname><given-names>S</given-names></name><name><surname>Niezgoda</surname><given-names>M</given-names></name><name><surname>G&#x00F3;mez</surname><given-names>J</given-names></name><name><surname>Laguna-Torres</surname><given-names>VA</given-names></name><etal/></person-group> <article-title>Evidence of rabies virus exposure among humans in the Peruvian Amazon.</article-title> <source>Am J Trop Med Hyg</source>. <year>2012</year>;<volume>87</volume>:<fpage>206</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2012.11-0689</pub-id><pub-id pub-id-type="pmid">22855749</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="web">World Health Organization. Rabies &#x2013; Bulletin &#x2013; Europe, queries [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who-rabies-bulletin.org/site-page/queries">https://www.who-rabies-bulletin.org/site-page/queries</ext-link>. [Pristupljeno 21. 10. 2022.]</mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vodopija</surname><given-names>R</given-names></name><name><surname>Te&#x0161;i&#x0107;</surname><given-names>V</given-names></name><name><surname>Kosanovi&#x0107;</surname><given-names>ML</given-names></name><name><surname>Bedekovi&#x0107;</surname><given-names>T</given-names></name><name><surname>Su&#x0161;ec</surname><given-names>I</given-names></name></person-group>. <article-title>Rad Referentnog centra za bjesno&#x0107;u te antirabi&#x010D;ne ambulante Nastavnog zavoda za javno zdravstvo &#x201E;Dr. Andrija &#x0160;tampar&#x201C; u razdoblju od 2008. do 2013. godine.</article-title> <source>Infektol Glas</source>. <year>2014</year>;<volume>34</volume>:<fpage>117</fpage>&#x2013;<lpage>32</lpage>.</mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="other">Madi&#x0107; J, Barbi&#x0107; Lj, Lojki&#x0107; I. Terrestrial rabies eliminated in Croatia &#x2013; a historical overview. Rad Hrvatske akademije znanosti i umjetnosti. Medicinske znanosti. 2020;544:64-76. <pub-id pub-id-type="doi">10.21857/yrvgqtejr9</pub-id>.<pub-id pub-id-type="doi">10.21857/yrvgqtejr9</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lojki&#x0107;</surname><given-names>I</given-names></name><name><surname>Cac</surname><given-names>Z</given-names></name><name><surname>Bedekovi&#x0107;</surname><given-names>T</given-names></name><name><surname>Lemo</surname><given-names>N</given-names></name><name><surname>Brstilo</surname><given-names>M</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Diversity of currently circulating rabies virus strains in Croatia.</article-title> <source>Berl Munch Tierarztl Wochenschr</source>. <year>2012</year>;<volume>125</volume>:<fpage>249</fpage>&#x2013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">22712423</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vodopija</surname><given-names>R</given-names></name><name><surname>Sokol</surname><given-names>K</given-names></name><name><surname>Lohman Jankovi&#x0107;</surname><given-names>I</given-names></name><name><surname>Su&#x0161;ec</surname><given-names>I</given-names></name></person-group>. <article-title>Oralna vakcinacija lisica protiv bjesno&#x0107;e u Republici Hrvatskoj &#x2013; koliko smo uspje&#x0161;ni do sada?</article-title> <source>Infektol Glas</source>. <year>2016</year>;<volume>36</volume>:<fpage>17</fpage>&#x2013;<lpage>26</lpage>.</mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="other">&#x0160;imi&#x0107; I. Prisutnost virusa u populacijama &#x0161;i&#x0161;mi&#x0161;a u Hrvatskoj [disertacija]. Zagreb: Sveu&#x010D;ili&#x0161;te u Zagrebu, Prirodoslovno-matemati&#x010D;ki fakultet, 2019.</mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="other">Bedekovi&#x0107; T, Lohman Jankovi&#x0107; I, &#x0160;imi&#x0107; I, Kre&#x0161;i&#x0107; N, Lojki&#x0107; I, Su&#x010D;ec I, et al. Control and elimination of rabies in Croatia. PLoS One. 2018;20;13:e0204115. doi: <pub-id pub-id-type="doi">10.1371/journal.pone</pub-id>.</mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="other">Ministarstvo poljoprivrede. Naredba o mjerama za&#x0161;tite zdravlja &#x017E;ivotinja od zaraznih i nametni&#x010D;kih bolesti i njihovom financiranju u 2021. godini. Nar Nov 2/2021.</mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="book">Briggs JD, Nagarajan T, Rupprecht CE. <italic>Rabies</italic>. Rabies Vaccines. U: Jackson CA. Rabies. Scientific basis of the disease and its management. Cambridge: Academic Press; 2013, str. 445&#x2013;79.</mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="web">Agencija za lijekove i medicinske proizvode. Rabipur pra&#x0161;ak i otapalo za otopinu za injekciju u napunjenoj &#x0161;trcaljki, cjepivo protiv bjesno&#x0107;e, inaktivirano. Zagreb; 2020. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.halmed.hr/Lijekovi/Baza-lijekova/Rabipur-prasak-i-otapalo-za-otopinu-za-injekciju-u-napunjenoj-strcaljki-cjepivo-protiv-bjesnoce-inaktivirano/12694/https:/">http://www.halmed.hr/Lijekovi/Baza-lijekova/Rabipur-prasak-i-otapalo-za-otopinu-za-injekciju-u-napunjenoj-strcaljki-cjepivo-protiv-bjesnoce-inaktivirano/12694/https:/</ext-link>. [Pristupljeno 21. 10. 2022.]</mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanlon</surname><given-names>CA</given-names></name><name><surname>Kuzmin</surname><given-names>IV</given-names></name><name><surname>Blanton</surname><given-names>JD</given-names></name><name><surname>Weldon</surname><given-names>WC</given-names></name><name><surname>Manangan</surname><given-names>JS</given-names></name><name><surname>Rupprecht</surname><given-names>CE</given-names></name></person-group>. <article-title>Efficacy of rabies biologics against new lyssaviruses from Eurasia.</article-title> <source>Virus Res</source>. <year>2005</year>;<volume>111</volume>:<fpage>44</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2005.03.009</pub-id><pub-id pub-id-type="pmid">15896401</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="web">Hrvatski zavod za javno zdravstvo. Program imunizacije, seroprofilakse i kemoprofilakse za posebne skupine stanovni&#x0161;tva 2020 Zagreb [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hzjz.hr/wp-content/uploads/2020/01/Provedbeni-program_-imunizacija-2020.-Program-2.pdf">https://www.hzjz.hr/wp-content/uploads/2020/01/Provedbeni-program_-imunizacija-2020.-Program-2.pdf</ext-link>. [Pristupljeno 21. 10. 2022.]</mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="web">Nastavni zavod za javno zdravstvo Dr. <italic>Andrija &#x0160;tampar</italic>. Obilje&#x017E;avanje Svjetskog dana borbe protiv bjesno&#x0107;e, 28. rujna 2017 [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.stampar.hr/hr/obiljezavanje-svjetskog-dana-borbe-protiv-bjesnoce-28-rujna-2017">http://www.stampar.hr/hr/obiljezavanje-svjetskog-dana-borbe-protiv-bjesnoce-28-rujna-2017</ext-link>. [Pristupljeno 21. 10. 2022.].</mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vodopija</surname><given-names>R</given-names></name><name><surname>Racz</surname><given-names>A</given-names></name><name><surname>Pahor</surname><given-names>&#x0110;</given-names></name></person-group>. <article-title>The incidence of jackal bites and injuries in the Zagreb Anti rabies clinic during the 1995-2014 period.</article-title> <source>Acta Clin Croat</source>. <year>2016</year>;<volume>55</volume>:<fpage>151</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.20471/acc.2016.55.01.20</pub-id><pub-id pub-id-type="pmid">27333730</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="web">Ministarstvo poljoprivrede Republike Hrvatske. Program nadziranja infekcije virusom bjesno&#x0107;e u Republici Hrvatskoj. [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.veterinarstvo.hr/UserDocsImages//Zdravlje_zivotinja/Program%20nadziranja%20infekcije%20virusa%20bjesno%C4%87e%20u%20Republici%20Hrvatskoj.pdf">http://www.veterinarstvo.hr/UserDocsImages//Zdravlje_zivotinja/Program%20nadziranja%20infekcije%20virusa%20bjesno%C4%87e%20u%20Republici%20Hrvatskoj.pdf</ext-link>. [Pristupljeno 3. 4. 2023.]</mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="web">Ministarstvo poljoprivrede Uprava veterinarstva. Oralna vakcinacija lisica u Hrvatskoj. [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.veterinarstvo.hr/UserDocsImages/Zdravlje_zivotinja/ORV/Brosura2012.pdf">http://www.veterinarstvo.hr/UserDocsImages/Zdravlje_zivotinja/ORV/Brosura2012.pdf</ext-link>. [Pristupljeno 21. 10. 2022.].</mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="web">World Health Organization. Rabies &#x2013; Bulletin &#x2013; Europe [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who-rabies-bulletin.org/news/re-emergence-rabies-bosnia-herzegovina">https://www.who-rabies-bulletin.org/news/re-emergence-rabies-bosnia-herzegovina</ext-link>. [Pristupljeno 21. 10. 2022.]</mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="web">Provedbena uredba komisije (eu) 2021/620 od 15. travnja 2021. Prilog iii; Infekcija virusom bjesno&#x0107;e (rabv). Dr&#x017E;ave &#x010D;lanice ili njihove zone koje imaju status dr&#x017E;ave ili zone slobodne od RABV-a. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://eur-lex.europa.eu/legal-content/HR/TXT/?uri=CELEX:32021R0620">https://eur-lex.europa.eu/legal-content/HR/TXT/?uri=CELEX:32021R0620</ext-link>. [Pristupljeno 21. 10. 2022.]</mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goszczy&#x0144;ski</surname><given-names>J</given-names></name></person-group>. <article-title>Home ranges in red fox: territoriality diminishes with increasing area.</article-title> <source>Acta Theriol (Warsz)</source>. <year>2002</year>;<volume>47</volume> <supplement>Supl 1</supplement>:<fpage>103</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/BF03192482</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar-Seti&#x00E9;n</surname><given-names>A</given-names></name><name><surname>Leon</surname><given-names>YC</given-names></name><name><surname>Tesoro</surname><given-names>EC</given-names></name><name><surname>Kretschmer</surname><given-names>R</given-names></name><name><surname>Brochier</surname><given-names>B</given-names></name><name><surname>Pastoret</surname><given-names>PP</given-names></name></person-group>. <article-title>Vaccination of vampire bats using recombinant vaccinia-rabies virus.</article-title> <source>J Wildl Dis</source>. <year>2002</year>;<volume>38</volume>:<fpage>539</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.7589/0090-3558-38.3.539</pub-id><pub-id pub-id-type="pmid">12243138</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
